BMS Bolsters Cardiovascular Pipeline with Potential US$2.075 B Purchase of Cardioxyl
By Heather Cartwright & Rohit Khera
Pharma Deals Review: Vol 2015 Issue 11 (Table of Contents)
Published: 13 Nov-2015
DOI: 10.3833/pdr.v2015.i11.2131 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Looking to sustain its cardiovascular disease franchise in the long-term, Bristol-Myers Squibb (BMS) has agreed to buy the rather low-profile Cardioxyl Pharmaceuticals in return for upfront and near-term milestone payments of US$300 M and potential additional consideration of up to US$1...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS